Transient Anti-CD40L Co-Stimulation Blockade Prevents Immune Responses against Human Bullous Pemphigoid Antigen 2: Implications for Gene Therapy
- 1 May 2009
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 129 (5) , 1203-1207
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Human Bullous Pemphigoid Antigen 2 Transgenic Skin Elicits Specific IgG in Wild-Type MiceJournal of Investigative Dermatology, 2007
- Intravenously Injected Human Fibroblasts Home to Skin Wounds, Deliver Type VII Collagen, and Promote Wound HealingMolecular Therapy, 2007
- Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cellsNature Medicine, 2006
- Fibroblasts as Target Cells for DEB Gene TherapyJournal of Investigative Dermatology, 2006
- Tolerance Induction by the Blockade of CD40/CD154 Interaction in Pemphigus Vulgaris Mouse ModelJournal of Investigative Dermatology, 2006
- Collagenous Transmembrane Proteins: Recent Insights into Biology and Pathology*Journal of Biological Chemistry, 2005
- The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challengeInternational Immunology, 2004
- Suppression of the Immune Response Against Exogenous Desmoglein 3 in Desmoglein 3 Knockout Mice: An Implication for Gene TherapyJournal of Investigative Dermatology, 2003
- Toward Epidermal Stem Cell-Mediated ex Vivo Gene Therapy of Junctional Epidermolysis BullosaHuman Gene Therapy, 2000
- Prevention of Collagen-Induced Arthritis with an Antibody to gp39, the Ligand for CD40Science, 1993